Study of Elunate® (Fruquintinib) in Chinese Patients With Advanced CRC

• Status: Recruiting
• Trial end date: 2023-02-28
• Target enrollment: 0
• Participant gender: All

Summary

A phase IV study to characterize safety of Elunate® (Fruquintinib) in Chinese patients

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hutchison Medipharma Limited

Criteria

Inclusion Criteria:

• Basic inclusion criteria for both cohort 1&cohort 2:

• Currently using Elunate® or will use Elunate® within a week;

• Provision of informed consent by the patient.

Cohort 1: Besides 2 criteria above, there're 3 more inclusion criteria for Cohort 1:

• Diagnosed metastatic colorectal cancer;

• ECOG PS ≤2 (0-2)；

• Patients are suitable to use Elunate® according to investigator's judgement. Cohort 2:

Patients only meet 2 basic inclusion criteria and suitable to use Elunate® according to investigator's judgement could be enrolled in cohort 2.

Exclusion Criteria:

• Exclusion criteria for both cohort 1& cohort 2:

• Unsuitable for the experiment according to investigator's judgement.